BEIJING — (Marketwire) — 08/28/12 — Hundreds of Western and Asian clinical development executives from the pharmaceutical, biotech, and CRO industry will gather on November 6-8 in Beijing to attend the industry-s largest annual international conference covering China-s booming clinical development industry.
The focus of “CHINA TRIALS 5: Global Clinical Development Summit” is unique, going well beyond topics and offering a unique blend of over 100 global speakers, who will share strategies on how to solve the challenges facing multinational and local companies doing global and regional in China. Topics on how to improve operations, manage relationships with Chinese KOLs and enhancing interactions with the Chinese , will be discussed in detail.
Conference topics include:
What Should Industry Really Expect From Early Phase Trials in China?
Regulatory Updates for Drug Approvals in China
Regional Asia-Pacific Drug Development
Comparing & Contrasting Principal Investigators from the US, Asia Pacific and China
Developing Drugs Together: Partnerships Between Global & Chinese Biopharmas
What Should Industry Really Expect From Early Phase Trials in China?
Medical Affairs and Marketing for Global Trials
Capacity and Capability Building for Global Trials
An international speaking faculty of over 100 speakers from over 40 pharma and biotech companies includes Allergan, Amgen, Astellas, Bayer, Celgene, Daiichi-Sankyo, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and many more.
Every major company from the CRO and clinical software areas will be exhibiting including Quintiles, Covance, LabCorp, Parexel, RPS, PPD, Oracle, ICON, and many more.
The conference agenda and registration information can be found by visiting the conference website at . Some speaking opportunities remain and sponsorship/exhibition opportunities are still available. To explore these opportunities further, please contact the organizer Jon E. Liong at or call 1-732-917-0664.
Jon E. Liong
1-732-917-0664